Children leuprolide will stop having an effect on a child treated for central precocious puberty soon after the child stops using it, and puberty will advance normally.

Albion 1997: Magnesium: mineral link to energy. Albion Research Notes 1997; 6 1 ; [Accessed 2007-02-27]. Available from: : albion-an human Newsletter 1997January Firoz M, Graber M. Bioavailability of US commercial magnesium preparations. Magnesium Research 2001; 14 4 ; : 257-262! Table II. Breakpoint concentrations of antibiotics mg L ; for Enterobacteriaceae and Pseudomonas spp. Breakpoint concentration mg L ; Agents Dose Cmax mg L ; % protein binding f T h ; susceptible resistant. Figure 3. Stripchart A ; , raster plot and perievent histogram B ; of a postcocaine inhibitory response in the absence of an anticipatory response by an NAS neuron. The decrease in spike activity begins about 5 set after cocaine infusion. The short vertical lines above the stripcharts represent lever presses that activated the pump for intravenous cocaine infusion. Note that the inhibition of spike activity gradually decayed following cocaine administration over the course of about 5 min. Upon reinstatement of baseline firing rates, the animal reliably self-administered cocaine. between the anticipatory neuronal responses in the NAS and lever pressing for cocaine self-administration was evaluated off line with frame-by-frame analysis of videotaped lever-pressing behaviors for cocaine self-administration. Behaviors related to lever pressing were fractionated into the following categories, which typically occurred in a temporal sequence l-6 ; : 1 ; turning to lever, whose onset was defined as when the rat interrupted stereotyped behaviors to orient and move toward the side of the chamber where the lever was located; 2 ; facing lever, in which the animal, now having approached the lever, often remained fixed in place for a short period of time; this was usually followed by 3 ; raising head to lever, at which time the animal moved its head in the direction of the lever, with its forelimbs still on the floor; at this time, a 4 ; rearing to lever interval began when a forelimb was lifted off the floor-this interval terminated when a forelimb made contact with the lever; 5 ; lever tofloor consisted of the animal, already touching the lever, pressing the lever, and removing its forelimb s ; from the lever and placing them on the floor, thereby completing behaviors specific to lever pressing; at this point, the animals typically were soon 6 ; turning away from lever in the direction of another side of the cage. Successful lever pressing was indicated to the animal by an and levalbuterol. Leuprolide online

Packed columns of Kieselgel 60, particle size 0.2-0.5 mm E. Merck A. G., Darmstadt, W. Germany ; . Each gram of lipid was chromatographed on 20 g silica and eluted with light petroleum 40-60 ; .A vitamin K-containing fraction that included the internal standard and other lipids was obtained by eluting with a mixture of light-petroleumdiethyl ether 97: 3, vol vol ; . After removal of solvents in a rotary evaporator, the vitamin K-containing fraction was dissolved in 50100 Af the mobile phase table 1 ; and sub o jected to semipreparative HPLC on columns containing either microparticulate silica Partisil-5 ; or an amino-cyano-bonded phase Partisil-10 PAC ; . Systems of semiprepara tive HPLC employed in this stage of the as say for phylloquinone are shown in table 1. Samples were injected onto columns in 2550 il the mobile phase, and the fraction of of the eluant that corresponded to the reten tion times of phylloquinone and internal standard was collected. The fraction collected from the semipre parative HPLC step was evaporated to dryness under nitrogen, redissolved in 50-100. Marci et al. 2005 ; conducted a prospective RCT randomized 1: ; . The poor responders oestradiol concentrations 600 pg ml on the day of HCG administration and the number of retrieved oocytes 3 after a previous standard long protocol with GnRHa ; were divided into two groups. Group A patients n 30; age 39 3.1 ; were stimulated with a standard long protocol using down-regulation with GnRHa, an injection of 3.75 mg leuprolide Enantone: Takeda, Italy ; , and an s.c. injection of recombinant FSH Gonal-F: Serono, Italy ; at a dose of 375 IU daily from day 3 of the next cycle. In group B n 30; age 38.8 2.9 ; , ovarian stimulation started at day 2 with recombinant FSH at a dose of 375 IU. The GnRH-ant cetrorelix Cetrotide: Serono, Switzerland ; , 0.25 mg per day, was then administered when the two leading follicles had reached 14 mm in diameter, irrespective of the day of the cycle, and continued until the day of HCG injection. The number of oocytes retrieved was found to be significantly increased P 0.022 ; in the GnRH-ant group 5.6 1.6 ; with respect to GnRHa long protocol group 4.3 2.2 ; . No information about basal FSH and the number of mature oocytes was reported. Cheung et al. 2005 ; reported a prospective, RCT computergenerated randomization concealed in opaque envelopes ; . A research nurse coordinated the randomization process and and levamisole. Buy leuprolide online Figure 6. Immunocytochemistry of Bcl-2 expression in endometrial cell cultures from subjects with endometriosis after treatment with leuprolide acetate LA ; and Antide. Endometrial epithelial cells from patients with endometriosis were plated in cell chamber slides under basal conditions A ; or after treatment with LA 1000 ng ml B ; , Antide 105 M C ; or combination of Antide with LA D ; . negative control E ; , normal goat immunoglobulin G IgG ; was used instead of primary antibody magnification: 600. Buy leuprolide

Results We identified a total of nine studies that compared medical treatment with danazol or GnRHa goserelin, leuprolide acetate, triptorelin ; with no treatment in preparation for hysteroscopic endometrial resection, myomectomy or metroplasty Table I ; . Only one study was described as randomized and indicated the method of allocation to treatment; the others were comparative studies in which the modality of treatment allocation was not specified. Danazol was used in three studies Magos et al., 1991; Petrucco and Fraser, 1992; Serden and Brooks, 1992 ; . Goserelin was used in five studies Donnez et al., 1990; Petrucco and Fraser, 1992; Vercellini et al., 1993, 1994, 1996 ; , leuprolide acetate in two Serden and Brooks, 1992; Perino et al., 1993 ; and triptorelin in one Tantini et al., 1994 ; . Most of the studies considered medical treatment in preparation for endometrial resection; in two studies it was given before myomectomy and in three before metroplasty. Mean intraoperative fluid absorption reported in the studies are shown in Table II. One study Magos et al., 1991 ; analysed the efficacy of danazol in reducing intraoperative fluid absorption in endometrial resection: its result suggests a reduction in fluid absorption 572 ml ; in women treated with danazol compared with untreated women. Two studies reported the efficacy of goserelin in reducing fluid absorption in endometrial resection: in both, fluid absorption was less in those subjects who underwent goserelin treatment. One study Perino et al., 1993; not shown in Table II ; reported values of mean fluid infusion but not absorption ; in women treated with leuprolide acetate 3600 ml ; versus untreated controls 7400 ml ; in preparation for endometrial resection and levemir. No 5, 622, 657 teaches one application of this method for the semi-continuousmanufacturing of peptide microcapsules, including leuprolide acetate.
What do these words mean some definitions ; ? Anal sphincter Anus Areflexic bowel A circular band of muscle that keeps the outlet of the rectum closed, like a drawstring on a purse. The outlet of the rectum lying between the fold of the buttocks A pattern of bowel dysfunction caused by injury to the nerves that travel from the spinal cord to the bowel. No reflex bowel processes are possible. Also called flaccid bowel or Lower Motor-Neuron LMN ; bowel. A person with this condition cant feel the need to have a bowel movement, the rectum doesnt empty by an automatic reflex action, and the anal sphincter doesnt close as tightly as it did to keep stool in. Any device that increases the independence of a person with a disability. An example is a digital stimulator, which helps a person with limited hand function to be more independent with bowel care. Also called adaptive device. Any movement that increases the speed of bowel care or the amount of stool produced. Includes abdominal massage, forward and sideways bending, push-ups, digital rectal stimulation and manual evacuation, An abnormal response to a problem in the body below a spinal cord injury that causes high blood pressure. Its most likely to happen if the SCI is at or above the 6th thoracic vertebra T6 ; . The intestine is a tube-like structure that propels and store food and waste. It extends from the stomach to the rectum, also called the gut or the gastrointestinal tract. Unplanned or uncontrolled bowel action, loss of stool or leakage causing staining of underwear or pad. Also called faecal incontinence. Passage of the stool out of the body. See defaecation. A total treatment plan designed to empty the bowels at a regular and predictable time through bowel care, to prevent or cut down on bowel accidents, and to keep bowel-related health and other problems to a minimum. The components of a bowel programme are diet, fluid intake, activity level, medications, and a consistent routine for bowel care. The process of triggering and assisting a bowel movement. Bowel care is part of a bowel programme. Bowel care can include any or all of the following steps: getting ready, positioning, checking for stool, inserting stimulant medications, performing digital stimulation or manual evacuation, and cleaning up. The large intestine. A surgical opening from the intestine through the abdominal wall that allows stool to be pushed out into an attached, disposable bag. This opening is built by disconnecting the colon from the rectum and connecting it to the abdominal wall. A condition in which stools are hard, do not pass as often less than three times per week ; , as completely, or as easily as they could. A condition associated with loose, watery or frequent bowel movements and levetiracetam. Keflex Cephalexin ; Keppra Levetiracetam ; Kerlone Betaxolol Hydrochloride ; Ketamine HCl Ketalar ; Ketoconazole Nizoral ; Ketoprofen Orudis ; Ketorolac Tromethamine Toradol Oral ; Kineret Anakinra ; Klaron Sodium Sulfacetamide Lotion KlorCon Potassium Chloride ; Kogenate FS Antihemophilic Factor Recombinant Korean Panax ; Ginseng Ginseng ; Kytril Granisetron ; Labetalol Trandate ; Lacrisert Cellulose ; Lactated Ringer's and 5% Dextrose Inj Lactated Ringers in 5% Lactated Ringers in 5% Dextrose Lactated Ringer's and 5% Dextrose Lactulose Cephulac ; Lamisil Terbinafine ; Lamivudine Zidovudine Combivir ; Lamprene Clofazimine ; Lansoprazole Prevacid ; Lansoprazole, Amoxicillin and Clarithromycin Prevpac ; Lapatinib Tykerb ; Laronidase Aldurazyme ; Latanoprost Xalatan ; Lenalidomide Revlimid ; Lescol Fluvastatin Sodium ; Letrozole Femara ; Leucovorin Calcium Leucovorin Calcium ; Leukine Sargramostim ; Leuprolide Acetate Lupron Depot ; Leuprolide Acetate for Depot Suspension Lupron Depot 7.5 mg ; Leuprolide Acetate Inj Lupron ; Leuprolide Acetate Inj Lupron Pediatric ; Levalbuterol Xopenex ; Levamisole Hydrochloride Ergamisol ; Levemir Insulin Detemir ; Kepivance Palifermin ; Keppra Injection Levetiracetam ; Ketalar Ketamine HCl ; Ketek Telithromycin ; Ketoconazole Cream Nizoral Cream ; Ketorolac tromethamine Acular ; Ketotifen Fumarate Zaditor ; Kinevac Sincalide ; Klonopin Clonazepam ; Koate Antihemophilic Factor ; Konyne Factor IX Complex ; Kwell Lindane Lotion ; Kytril Inj Granisetron Hydrochloride ; LacHydrin Lactic Acid ; Lactated Ringer's Lactated Ringer's Inj ; Lactated Ringer's Inj Lactated Ringer's ; Lactic Acid LacHydrin ; Lamictal Lamotrigine ; Lamivudine Epivir ; Lamotrigine Lamictal ; Lanoxin Digoxin ; Lansoprazole Prevacid NapraPAC ; Lantus Insulin Glargine [rDNA origin] Inj ; Lariam Mefloquine ; Lasix Furosemide ; Leflunomide Arava ; Lepirudin Refludan ; LescolXL Fluvastatin ; Leucovorin Leucovorin ; Leukeran Chlorambucil ; Leuprolide Acetate Eligard ; Leuprolide Acetate for Depot Suspension Lupron Depot 11.25 mg ; Leuprolide Acetate Implant Viadur ; Leuprolide Acetate Inj Lupron Depot 3.75 mg ; Leustatin Cladribine ; Levalbuterol Tartrate Xopenex HFA ; Levaquin Levofloxacin ; Levetiracetam Keppra.
Robertson et al Dopamine 0-Hydroxylase Deficiency However, long-term treatment with DOPS in this disorder is associated with intraneuronaJ restoration of norepinephrine, which is released on assuming the upright posture. Thus, DOPS in DBH deficiency appears to be far more effective than any other therapy for any form of autonomic dysfunction.31-41-42'44 Dopamine J-Hydroxylase Deficiency: Implications and levonorgestrel. Property Description: A traditional semi detached house of rendered brick construction, surmounted by a hipped slate clad roof, having a single storey extension at the rear and benefiting from UPVC double glazed windows and gas-fired central heating. The property requires modernisation and repair. Ivyhouse Lane itself leads directly off Birmingham New Road A4123 ; , and the property is located approximately three and a half miles to the south of Wolverhampton City Centre.
Treated, precocious puberty can result in short stature and significant social problems for children undergoing sexual maturation years before their peers.1, 2 Pulsatile secretion of endogenous gonadotropin-releasing hormone GnRH ; results in luteinizing hormone LH ; and follicle-stimulating hormone FSH ; release from the pituitary and progression of puberty, 3 whereas the tonic stimulus of a long-acting GnRH analog causes an initial surge of gonadotropin release, followed by suppression of pituitary gonadotropin production and release.4, 5 Depot leuprolide Depot-Lupron, TAP Pharmaceuticals, Deerfield, IL ; , a commonly used long-acting GnRH analog, is given by monthly intramuscular IM ; injection and is slowly released into the circulation to provide such tonic suppressive levels. Depot leuprolide consists of leuprolide encased in microspheres of a glycolic and lactic acid copolymer. Free leuprolide is also present in the preparation6 and is absorbed into the circulation within minutes of injection, while the microspheres slowly release leuprolide, providing steady, suppressive levels. Pharmacokinetic data in adults receiving therapy for prostate4, 5 and breast cancer7 show that free leuprolide in the depot preparation rapidly enters the serum, peaking at 45 to minutes. In these studies in adult cancer patients, a rise in serum LH and FSH was documented 12 hours after injection but was not studied at earlier time points. Pharmacokinetic data for depot leuprolide in children have not been published. Dosage of depot leuprolide varies widely in clinical practice in children, ranging from 3.75 to 15 mg at 2- to 4-week intervals. Insufficient doses can be counterproductive, as the waxing and waning of hormone levels may actually mimic the stimulatory GnRH pulses that advance puberty.8, 9 Frequent testing to ensure adequacy of therapy and to optimize the dose is important in monitoring treated patients.3 Patients receiving depot leuprolide therapy are monitored clinically, through assessment of linear growth, sexual maturation, and bone age. However, these parameters may correlate poorly with the degree of suppression of gonadotropins. In addition, there is considerable lag time in bone age advancement as well as significant variability in bone-age readings among examiners.10 Because estradiol is difficult to assay accurately, measurement of LH is the key biochemical assessment of pubertal status. Spontaneous or unstimulated LH concentrations, although potentially useful in diagnosis of CPP, have and levorphanol.

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60. Jacobson MA, French M. Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy. AIDS 1998; 12: Suppl A: S157-S163. 3. Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001; 135: 17-26. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4 + T cell homeostasis and function in advanced HIV disease. Science 1997; 277: 112-6. Lederman MM, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group protocol 315. J Infect Dis 1998; 178: 70-9. Lorenzi P, Opravil M, Hirschel B, et al. Impact of drug resistance mutations on virologic response to salvage therapy: Swiss HIV Cohort Study. AIDS 1999; 13: F17-F21. 7. D'Aquila RT, Johnson VA, Welles SL, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995; 122: 401-8. Zolopa AR , Shafer RW, Warford A, et al. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med 1999; 131: 813-21. Acute HIV Infection and Early Disease Research Program AIEDRP ; . Seattle: Statistical Center for HIV AIDS Research and Prevention SCHARP ; , 2002. Accessed July 15, 2002, at : aiedrp.fhcrc . ; 10. Janssen RS, Satten GA, Stramer SL, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 1998; 280: 42-8. [Erratum, JAMA 1999; 281: 1893.].

Various CAT have complex and incompletely understood effects of CsA metabolism and CsA blood levels that may indirectly increase the level of immunosuppression. Both diltiazem and VP compete with CsA for the cytochrome P-450 pathway 9, 10 ; . Thus, in the presence of CAT, CsA metabolism is decreased and CsA blood levels are increased. At least part of the beneficial effect of these two CAT on and licorice and leuprolide.
Division of Nephrology, Department of Medicine, versity of California, San Diego, La Jolla, CA. J. Am. Soc. Nephrol. 1990: 1: 91-98.
And the region of interest is discrete, a decrease in spacing of sections is advisable. Prescan localization can be successfully acomplished in most situations by means of clinical history and external landmarks as outlined in the clinical protocols. The initial patient position in virtually all studies is supine; however, additional views may occasionally provide important diagnostic information. Oral and intravenous contrast agents as well as spasmolytic drugs should be used judiciously. A knowledge and linezolid. CDR018 PPA ; Technical Specification of Data Files R2.2.doc NHS Connecting for Health-ETP EIM-0015.01.
THE JOURNAL OF DENTAL RESEARCH, VOL. I, NO.

WARNINGS Initially, LUPRON DEPOT, like other LH-RH agonists, causes increases in serum levels of testosterone to approximately 50% above baseline during the first week of treatment. Transient worsening of symptoms, or the occurrence of additional signs and symptoms of prostate cancer, may occasionally develop during the first few weeks of LUPRON DEPOT treatment. A small number of patients may experience a temporary increase in bone pain, which can be managed symptomatically. As with other LH-RH agonists, isolated cases of ureteral obstruction and spinal cord compression have been observed, which may contribute to paralysis with or without fatal complications. For patients at risk, initiation of therapy with daily LUPRON leuprolide acetate ; Injection See DOSAGE AND ADMINISTRATION section in the LUPRON Injection labeling. ; for the first two weeks to facilitate withdrawal of treatment may be considered. If spinal cord compression or renal impairment develops, standard treatment of these complications should be instituted. PRECAUTIONS Information for Patients An information pamphlet for patients is included with the product. General Patients with metastatic vertebral lesions and or with urinary tract obstruction should be closely observed during the first few weeks of therapy. See WARNINGS section. ; Laboratory Tests Response to LUPRON DEPOT-4 Month 30 mg should be monitored by measuring serum levels of testosterone, as well as prostate-specific antigen. In the majority of patients, testosterone levels increased above baseline during the first week, declining thereafter to baseline levels or below by the end of the second week. Castrate levels were reached within two to four weeks and once achieved were maintained in most 45 49 ; patients for as long as the patients received their injections. See CLINICAL STUDIES and ADVERSE REACTIONS. ; Drug Interactions See CLINICAL PHARMACOLOGY, Pharmacokinetics. Drug Laboratory Test Interactions Administration of LUPRON DEPOT in therapeutic doses results in suppression of the pituitary-gonadal system. Normal function is usually restored within three months after treatment is discontinued. Due to the suppression of the pituitarygonadal system by LUPRON DEPOT, diagnostic tests of pituitary gonadotropic and gonadal functions conducted during treatment and for up to three months after discontinuation of LUPRON DEPOT may be affected. Carcinogenesis, Mutagenesis, Impairment of Fertility Two-year carcinogenicity studies were conducted in rats and mice. In rats, a dose-related increase of benign pituitary hyperplasia and benign pituitary adenomas was noted at 24 months when the drug was administered subcutaneously at high daily doses 0.6 to 4 mg kg ; . There was a significant but not dose-related increase of pancreatic islet-cell adenomas in females and of testicular interstitial cell adenomas in males highest incidence in the low dose group ; . In mice no pituitary abnormalities were observed at a dose as high as 60 mg kg for two years. Patients have been treated with leuprolide acetate for up to three years with doses as high as 10 mg day and for two years with doses as high as 20 mg day without demonstrable pituitary abnormalities. P162 RA5214 ; Evidence For Immunoregulation In The Anterior Chamber Of The Eye During Corneal Graft Rejection SM Nicholls, S Banerjee, DL Easty and AD Dick Unit of Ophthalmology, Department of Clinical Science at South Bristol, School of Medical Sciences, University Walk, Bristol, BS8 1TD, United Kingdom Background. The corneal endothelium and the leukocytes that destroy it during corneal graft rejection are exposed to the anterior chamber AC ; environment, which has immunoregulatory properties. This may alter the phenotype of infiltrating cells and influence the effector mechanism of endothelial cell rejection. The purpose of this investigation was to determine cell-surface and inflammatory cytokine phenotype of cells infiltrating the AC and adhering to the endothelium. Methods. Corneas from LEW strain rats were transplanted to PVG strain recipients. Animals were killed and cells were removed from the AC of transplanted eyes, stained with a range of antibodies to cell surface markers and the cytokines TNF , IFN and IL-10 and examined by flow cytometry. The phenotype of cells adhering to the endothelium was determined by immunocytochemistry. Results. Proportions of leukocyte subtypes in the AC by single staining were as follows: TCR 52% range 4262 ; , CD4 29% 27-30 ; , CD8 47% 45-48 ; , CD25 13% 8-18 ; , MHC class II 30%, CD161 NK ; 27% 25-28 ; , CD68 myeloid cell ; 21%, CD163 tissue macrophage ; 11% 10-12 ; and granulocyte 12% 10-13 ; . At least 90% of CD163 + macrophages were MHC II + . The CD161 + population comprised a 1: ratio of TCR + CD161low to TCR-CD161high cells and 50% of CD161 + cells were also CD8 + . 80-90% of TCR + cells, CD161 + cells and macrophages expressed TNF and at least 20% of each cell type expressed IL-10, suggesting co-expression of TNF and IL-10. In contrast there was negligible IFN expression. However, stimulation of AC cells for 4 hours with PMA and ionomycin induced IFN in 23% of cells, 43% of which were CD4 + . Fas ligand was expressed by endothelial cells. Cells adhering directly to the endothelium were mainly CD8 + T cells and CD163 + macrophages, with relatively few CD4 + cells, NK cells or CD25 + cells. Conclusions. 1 ; A mixed population of cells enters the AC, but the profile of cells adhering to the endothelium is restricted, consistent with apoptosis of leukocytes induced by endothelial cell expression of Fas ligand or other death receptor. 2 ; The AC environment suppresses IFN expression. 3 ; These immunomodulatory effects are insufficient to prevent rejection. Mutagenicity studies were performed with leuprolide acetate using bacterial and mammalian systems and levalbuterol.

Treatment satisfaction is a complex concept that requires adaptation to the specific cultural setting.There are many definitions of the concept of "treatment satisfaction", but all include elements that refer to the presence of an expectation or need of the patient and the extent to which this is fulfilled by taking the medication.The factors that determine satisfaction are usually grouped into four categories: patient expectations, patient characteristics demographics ; , psychosocial factors and patients' experience of interacting with the healthcare system. Reader, * Senior Resident, Department of Medicine, * Lecturer, Department of Obstetrics and Gynaecology, * Resident, Department of Pathology, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh - 202 002 U.P.

2. LHRH Agonists Goserilin Zoladex ; 3.6 mg SC Depot q28d or 10.8 mg SC Depot q84d Leuprolide Lupron-IM, Eligard-SC ; 7.5 mg IM SC Depot q28d or 22.5 mg IM SC Depot q84d or 30 mg IM SC Depot q120d Buserilin Suprefact ; 6.3 mg SC Depot q56d or 9.45 mg IM Depot q120d Note: Due to an initial rise in testosterone levels, patients should be given a nonsteroidal antiandrogen see below ; for 2-4 weeks at the same time as their first LHRH agonist dose 3. Non-steroidal Antiandrogen Agents Flutamide Euflex ; 250 mg PO TID Bicalutamide Casodex ; 50 mg PO daily, up to 150 mg PO daily to TID Nilutamide Anandron ; 50 mg PO BID or TID.

CANCER DRUG MANUAL Several drug monographs and patient information handouts have been revised. Cisplatin Monograph and Patient Information These have been extensively updated. BCG Monograph This has been updated to include information related to the GUBCGIFN protocol. Ready-to-use interferon contains preservatives that may inactivate BCG; this drug interaction has been noted in this monograph. Intravesical administration and dosing information has been added to the monograph. Capecitabine Monograph and Patient Information These have been revised to include information about cardiotoxicity. Approximately 3% of patients treated with capecitabine experience cardiotoxicity which often appears 2-3 days after therapy is initiated. The spectrum of cardiotoxicity is similar to that reported with 5-fluorouracil 5-FU ; and includes myocardial infarction, angina, cardiac failure and ECG changes. While the mechanism of capecitabine-related cardiotoxicity is not known, risk factors include a history of cardiotoxicity associated with 5-FU therapy and a prior history of coronary artery disease. Symptoms often resolve upon discontinuation of capecitabine. Docetaxel Monograph This has been revised to update stability information for the diluted solution for infusion. Docetaxel diluted in NS or D5W is stable for 4 hours at room temperature or refrigerated. LHRH Agonists Patient Information The patient handouts for buserelin, goserelin and leuprolide have been revised to delete the information on selfadministration of the daily injectable, which is no longer commonly used for the treatment of cancer of the prostate and breast. Also, leuprolide acetate SC injectable Eligard ; has been added to the leuprolide handout.